FS-Biolabs is a young innovative biotech company dedicated to leading the research and clinical translation of extracellular RAS therapies for the treatment of malignant diseases.
The FS-Biolabs team has discovered a novel mechanism by which cells express essential and vital proteins of the RAS family (KRAS, NRAS, and HRAS).
Our company envisions a new era of immunotherapy for cancer patients affected by conditions such as pancreatic cancer, breast cancer, prostate cancer, acute leukemias, lymphomas, and multiple myeloma.
Drug Development Pipeline
PLL04 – A first-in-class bispecific antibody targeting extracellular RAS proteins on cancer cells. This antibody can be administered every 20 to 30 days in an outpatient setting.
Developing the world’s first extracellular RAS-targeting antibodies for cancer therapy.
Focused on solid tumors, leukemias, and lymphomas.
E-Mail: martin.bumm@gmx.de
Address: FS-Biolabs, c/o Bumm UG, Rheinpromenade 4a, 40789 Monheim, Germany
©Urheberrecht. Alle Rechte vorbehalten.
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.